EADV preceptorship: Advances in dermatology

Journal of the European Academy of Dermatology and Venereology

Volumn 24, Issue SUPPL. 5, 2010, Pages 2-24

  Boehncke, W H ^a   Katsambas, A ^b   Ortonne, J P ^c   Puig, L ^d  

^a Department of Dermatology ^*  (Germany)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; B7 ANTIGEN; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFALIZUMAB; ETANERCEPT; ETRETIN; FOLIC ACID; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; METHOTREXATE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; PROTEIN; PSORALEN; PSORS1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; USTEKINUMAB;

ANOREXIA; ANTIBODY RESPONSE; BIOLOGICAL THERAPY; BONE MARROW DEPRESSION; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CREATININE BLOOD LEVEL; DENDRITIC CELL; DERMATOLOGY; DIARRHEA; DIET SUPPLEMENTATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ELASTOGRAPHY; EVIDENCE BASED MEDICINE; GENETIC SUSCEPTIBILITY; GINGIVA HYPERPLASIA; HUMAN; HYPERTENSION; HYPERTRICHOSIS; INFECTION RISK; KIDNEY FAILURE; LIVER DISEASE; LIVER FAILURE; LIVER FIBROSIS; LIVER TOXICITY; LOW DRUG DOSE; LUNG ALVEOLITIS; MALAISE; MEDICAL EDUCATION; MONOTHERAPY; NAIL DISEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PARESTHESIA; PATHOGENESIS; PATHOPHYSIOLOGY; PHOTOCHEMOTHERAPY; PHOTOTHERAPY; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS; PSORIATIC ARTHRITIS; PUVA; RECOMMENDED DRUG DOSE; REGISTER; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN CANCER; SKIN MANIFESTATION; T LYMPHOCYTE; TREMOR; ULTRAVIOLET B RADIATION; UNSPECIFIED SIDE EFFECT; VOMITING;

DERMATOLOGY; HUMANS; INCIDENCE; INTERDISCIPLINARY COMMUNICATION; PRECEPTORSHIP; PSORIASIS; VENEREOLOGY; WORLD HEALTH;

EID: 77955854949     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03787.x     Document Type: Review

References (151)

1. Lebwohl M. Psoriasis. Lancet 2003 361 : 1197 1204.
2. Tiilikainen A, Lassus A, Karvonen J et al. Psoriasis and HLA-Cw6. Br J Dermatol 1980 102 : 179 184.
3. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007 370 : 263 271.
4. Farber EM, Nall ML, Watson W. Natural history of psoriasis in 61 twin pairs. Arch Dermatol 1974 109 : 207 211.
5. Bowcock AM. Psoriasis genetics: the way forward. J Invest Dermatol 2004 122 : xv xvii.
6. Elder JT. Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis. Genes Immun 2009 10 : 201 209.
7. Nedoszytko B, Szczerkowska-Dobosz A, Zabłotna M et al. Associations of promoter region polymorphisms in the tumour necrosis factor-alpha gene and early-onset psoriasis vulgaris in a northern Polish population. Br J Dermatol 2007 157 : 165 167.
8. Reich K, Mössner R, König IR et al. Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1beta are associated with different subtypes of psoriasis characterized by early and late disease onset. J Invest Dermatol 2002 118 : 155 163.
9. Craven NM, Jackson CW, Kirby B et al. Cytokine gene polymorphisms in psoriasis. Br J Dermatol 2001 144 : 849 853.
10. Tsunemi Y, Saeki H, Nakamura K et al. Interleukin-12 p40 gene (IL12B) 3′-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris. J Dermatol Sci 2002 30 : 161 166.
11. Cargill M, Schrodi SJ, Chang M et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007 80 : 273 290.
12. Duffin KC, Krueger GG. Genetic variations in cytokines and cytokine receptors associated with psoriasis found by genome-wide association. J Invest Dermatol 2009 129 : 827 833.
13. Capon F, Di Meglio P, Szaub J et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007 122 : 201 206.
14. Nair RP, Henseler T, Jenisch S et al. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet 1997 6 : 1349 1356.
15. Duerr RH, Taylor KD, Brant SR et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006 314 : 1461 1463.
16. Becker KG, Simon RM, Bailey-Wilson JE et al. Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci USA 1998 95 : 9979 9984.
17. Lee FI, Bellary SV, Francis C. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol 1990 85 : 962 963.
18. Boehncke WH, Dressel D, Zollner TM et al. Pulling the trigger on psoriasis. Nature 1996 379 : 777.
19. Telfer NR, Chalmers RJ, Whale K et al. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol 1992 128 : 39 42.
20. Gudjonsson JE, Thorarinsson AM, Sigurgeirsson B et al. Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study. Br J Dermatol 2003 149 : 530 534.
21. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004 113 : 1664 1675.
22. Eyre RW, Krueger GG. Response to injury of skin involved and uninvolved with psoriasis, and its relation to disease activity: Koebner and 'reverse' Koebner reactions. Br J Dermatol 1982 106 : 153 159.
23. Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol 2000 1 : 159 165.
24. Setty AR, Curhan G, Choi HK. Smoking and the risk of psoriasis in women: Nurses' Health Study II. Am J Med 2007 120 : 953 959.
25. Richards HL, Ray DW, Kirby B et al. Response of the hypothalamic- pituitary-adrenal axis to psychological stress in patients with psoriasis. Br J Dermatol 2005 153 : 1114 1120.
26. Jariwala SP. The role of dendritic cells in the immunopathogenesis of psoriasis. Arch Dermatol Res 2007 299 : 359 366.
27. Bromley SK, Burack WR, Johnson KG et al. The immunological synapse. Annu Rev Immunol 2001 19 : 375 396.
28. Korn T, Bettelli E, Oukka M et al. IL-17 and Th17 Cells. Annu Rev Immunol 2009 27 : 485 517.
29. Griffiths CEM, Christophers E, Barker JN et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol 2007 156 : 258 262.
30. Reich K, Mrowietz U. Treatment goals in psoriasis. J Dtsch Dermatol Ges 2007 5 : 566 574.
31. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 19 : 210 216.
32. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005 152 : 861 867.
33. Smith CH, Barker JNWN. Psoriasis and its management. Br Med J 2006 333 : 380 384.
34. Gelfand JM, Troxel AB, Lewis JD et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007 143 : 1493 1499.
35. Gottlieb AB, Dann F, Menter A. Psoriasis and the metabolic syndrome. J Drugs Dermatol 2008 7 : 563 572.
36. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995 32 : 982 986.
37. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of psoriatic arthritis: a systematic review. J Rheumatol 2008 35 : 1354 1358.
38. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005 129 : 827 836.
39. Gelfand JM, Berlin J, Van Voorhees A et al. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003 139 : 1425 1429.
40. Schmitt JM, Ford DEl. Role of depression in quality of life for patients with psoriasis. Dermatology 2007 215 : 17 27.
41. Gladman DD, Antoni C, Mease P et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005 64 (Suppl 2 ii14 ii17.
42. Gottlieb A, Korman NJ, Gordon KB et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008 58 : 851 864. (Pubitemid 351509657)
43. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973 3 : 55 78.
44. Taylor W, Gladman D, Helliwell P et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006 54 : 2665 2673.
45. Gladman DD, Schentag CT, Tom BD et al. Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS). Ann Rheum Dis 2009 67 : 497.
46. Strong K, Mathers C, Leeder S et al. Preventing chronic diseases: how many lives can we save? Lancet 2005 366 : 1578 1582.
47. Gisondi P, Tessari G, Conti A et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007 157 : 68 73.
48. Gelfand J, Neimann AL, Shin DB et al. Risk of myocardial infarction in patients with psoriasis. J Am Med Assoc 2006 296 : 1735 1741. (Pubitemid 44547793)
49. Ludwig RJ, Herzog C, Rostock A et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007 156 : 271 276.
50. Boehncke S, Thaci D, Beschmann H et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007 157 : 1249 1251.
51. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005 352 : 1685 1695.
52. Ludwig RJ, Schultz JE, Boehncke WH et al. Activated, not resting, platelets increase leukocyte rolling in murine skin utilizing a distinct set of adhesion molecules. J Invest Dermatol 2004 122 : 830 836.
53. Davidovici BB, Sullivan-Whalen MM, Gilleaudeau P et al. Differing effect of systemic anti psoriasis therapies on platelet physiology - a case report and review of literature. BMC Dermatol 2010 10 : 2.
54. Tamagawa-Mineoka R, Katoh N, Kishimoto S. Platelet activation in patients with psoriasis: increased plasma levels of platelet-derived microparticles and soluble P-selectin. J Am Acad Dermatol 2010 62 : 621 626.
55. Naldi L, Chatenoud L, Linder D et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005 125 : 61 67.
56. Kirby B, Richards HL, Mason DL et al. Alcohol consumption and psychological distress in patients with psoriasis. Br J Dermatol 2008 158 : 138 140.
57. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005 115 : 1111 1119.
58. Boehncke WH, Boehncke S, Schön MP. Managing comorbid disease in patients with psoriasis. Br Med J 2010 340 : b5666. doi: 10.1136/bni.c147
59. Prodanovich S, Ma F, Taylor JR et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005 52 : 262 267.
60. Dixon WG, Watson KD, Lunt M et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007 56 : 2905 2912.
61. Jacobsson LT, Turesson C, Nilsson JA et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007 66 : 670 675.
62. Menter A, Gottlieb A, Feldman SR et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008 58 : 826 850. (Pubitemid 351509656)
63. Pathirana D, Ormerod AD, Saiag P et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009 23 (Suppl 2 5 70.
64. Sivanesan SP, Gattu S, Hong J et al. Randomized, double-blind, placebo-controlled evaluation of the efficacy of oral psoralen plus ultraviolet A for the treatment of plaque-type psoriasis using the Psoriasis Area Severity Index score (improvement of 75% or greater) at 12 weeks. J Am Acad Dermatol 2009 61 : 793 798.
65. Karrer S, Eholzer C, Ackermann G et al. Phototherapy of psoriasis: comparative experience of different phototherapeutic approaches. Dermatology 2001 202 : 108 115.
66. Gordon PM, Diffey BL, Matthews JN et al. A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J Am Acad Dermatol 1999 41 : 728 732.
67. Ozdemir M, Engin B, Baysal I et al. A randomized comparison of acitretin-narrow-band TL-01 phototherapy and acitretin-psoralen plus ultraviolet A for psoriasis. Acta Derm Venereol 2008 88 : 589 593.
68. Kircik L, Bagel J, Korman N et al. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. J Drugs Dermatol 2008 7 : 245 253.
69. Pang ML, Murase JE, Koo J. An updated review of acitretin - a systemic retinoid for the treatment of psoriasis. Expert Opin Drug Metab Toxicol 2008 4 : 953 964.
70. Laburte C, Grossman R, Abi-Rached J et al. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol 1994 130 : 366 375.
71. Ho VC, Griffiths CE, Albrecht G et al. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group. Br J Dermatol 1999 141 : 283 291.
72. Ho VC, Griffiths CE, Berth-Jones J et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol 2001 44 : 643 651.
73. van Roijen L, Verboom P, Redekop KW et al. The cost effectiveness of tapered versus abrupt discontinuation of oral cyclosporin microemulsion for the treatment of psoriasis. Pharmacoeconomics 2001 19 : 599 608.
74. Chaidemenos GC, Mourellou O, Avgoustinaki N et al. Intermittent vs. continuous 1-year cyclosporin use in chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2007 21 : 1203 1208.
75. Yoon HS, Youn JI. A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis. J Dermatolog Treat 2007 15 : 286 290.
76. Paul CF, Ho VC, McGeown C et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003 20 : 211 216.
77. Braun J, Kästner P, Flaxenberg P et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008 58 : 73 78.
78. Flytström I, Stenberg B, Svensson A et al. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008 158 : 116 121.
79. Heydendael V, Spuls PI, Opmeer BC et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003 349 : 658 665.
80. Saurat JH, Stingl G, Dubertret L et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008 158 : 558 566.
81. Saurat JH et al. EADV 2009, Berlin Germany, Abstract P1223.
82. Reich K et al. EADV 2009 Berlin, Germany, Abstract P1187.
83. Clinical Study Results. [WWW document] 2009. URL http://www. clinicalstudyresults.org/documents/company-study-9522-0.pdf (last accessed: 5 July 2010).
84. Hroch M, Chladek J, Simkova M et al. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment. J Eur Acad Dermatol Venereol 2008 22 : 19 24.
85. Warren R, Smith RL, Campalani E et al. Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. Br J Dermatol 2009 160 : 438 441.
86. Chládek J, Simková M, Vanecková J et al. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. Eur J Clin Pharmacol 2008 64 : 347 355.
87. Lucas J, Ntuen E, Pearce DJ et al. Methotrexate: understanding the risk in psoriasis patients. J Dermatolog Treat 2009 20 : 311 313.
88. Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol 2009 160 : 622 628.
89. Salim A, Tan E, Ilchyshyn A et al. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 2006 154 : 1169 1174.
90. Morgan SL, Baggott JE, Vaughn WH et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med 1994 121 : 833 841.
91. Baggott JE, Morgan SL. Methotrexate catabolism to 7-hydroxymethotrexate in rheumatoid arthritis alters drug efficacy and retention and is reduced by folic acid supplementation. Arthritis Rheum 2009 60 : 2257 2260.
92. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009 68 : 1100 1104.
93. Roenigk HH Jr., Auerbach R, Maibach H et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998 38 : 478 485.
94. Erickson AR, Reddy V, Vogelgesang SA et al. Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients. Arthritis Rheum 1995 38 : 1115 1119.
95. Walker AM, Funch D, Dreyer NA et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum 1993 36 : 329 335.
96. Phillips CA, Cera PJ, Mangan TF et al. Clinical liver disease in patients with rheumatoid arthritis taking methotrexate. J Rheumatol 1992 19 : 229 233.
97. Yazici Y, Sokka T, Kautiainen H et al. Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 2005 64 : 207 211.
98. Amital H, Arnson Y, Chodick G et al. Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate. Rheumatology (Oxford) 2009 48 : 1107 1110.
99. Lindsay K, Fraser AD, Layton A et al. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology (Oxford) 2009 48 : 569 572.
100. Svegliati-Baroni G, Bugianesi E, Bouserhal T et al. Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease. Gut 2007 56 : 1296 1301.
101. Hickman IJ, Macdonald GA. Impact of diabetes on the severity of liver disease. Am J Med 2007 120 : 829 834.
102. Mok MY, Ng WL, Yuen MF et al. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol 2000 18 : 363 368.
103. Baldo V, Baldovin T, Trivello R et al. Epidemiology of HCV infection. Curr Pharm Des 2008 14 : 1646 1654.
104. Gisondi P, Targher G, Zoppini G et al. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009 51 : 758 764.
105. Haukeland JW, Konopski Z, Linnestad P et al. Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol 2005 40 : 1469 1477.
106. Chalmers RJ, Kirby B, Smith A et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol 2005 152 : 444 450.
107. Maurice PD, Maddox AJ, Green CA et al. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen. Br J Dermatol 2005 152 : 451 458.
108. Laharie D, Zerbib F, Adhoute X et al. Diagnosis of liver fibrosis by transient elastography (FibroScan) and non-invasive methods in Crohn's disease patients treated with methotrexate. Aliment Pharmacol Ther 2006 23 : 1621 1628.
109. Berends MA, Snoek J, de Jong EM et al. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. Liver Int 2007 27 : 639 645.
110. Warren RB, Brown BC, Lavery D et al. Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre. Br J Dermatol 2009 160 : 162 169.
111. Gordon KB, Langley RG, Leonardi C et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006 55 : 598 606.
112. Menter A, Tyring SK, Gordon K et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008 58 : 106 115.
113. Gordon K et al. AAD 2010, Miami, Florida, USA; P3367.
114. Thaci D, Ortonne JP, Chimenti S et al. A Phase IIIb, multi-centre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriolbetamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE Study. Br J Dermatol 2010 Apr 2 [Epub ahead of print].
115. Katsambas A et al. EADV 2009, Berlin, Germany; P1169.
116. Thaci D et al. EADV 2009, Berlin, Germany; P824.
117. Mease P, Ory P, Sharp JT et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009 68 : 702 709.
118. Leonardi C, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003 349 : 2014 2022.
119. Papp KA, Tyring S, Lahfa M et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005 152 : 1304 1312.
120. Tyring S, Gordon KB, Poulin Y et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007 143 : 719 726.
121. Paller AS, Siegfried EC, Langley RG et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008 358 : 241 251.
122. Sterry W, Ortonne JP, Kirkham B et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010 340 : c147. doi:10.1136/bni.C147
123. Luger TA, Barker J, Lambert J et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2009 23 : 896 904.
124. Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004 51 : 534 542.
125. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. Lancet 2005 366 : 1367 1374.
126. Menter A, Feldman SR, Weinstein GD et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007 56 : 31.
127. Vultaggio A, Matucci A, Nencini F et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010 65 : 657 661.
128. Dalaker M, Bonesrønning JH. Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort. J Eur Acad Dermatol Venereol 2009 23 : 277 282.
129. Rich P, Griffiths CE, Reich K et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008 58 : 224 231.
130. Burmester G, Mease P, Dijkmans BA et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009 68 : 1863 1869.
131. Langly RG, Strober BE, Gu Y et al. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. Br J Dermatol 2010 162 : 1349 1358.
132. Katugampola RP, Lewis VJ, Finlay AY. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol 2007 156 : 945 950.
133. Puig L, Bordas X, Carrascosa JM et al. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis. Spanish psoriasis group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr 2009 100 : 277 286.
134. Abrams JR, Kelley SL, Hayes E et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000 192 : 681 694.
135. Gately MK, Renzetti LM, Magram J et al. The interleukin-12interleukin-12- receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 1998 16 : 495 521.
136. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003 3 : 133 146.
137. Di Cesare A, Di Meglio P, Nestle FO. The IL-23Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009 129 : 1339 1350.
138. Leonardi C, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-1223 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008 371 : 1665 1674.
139. Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-1223 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008 371 : 1675 1684.
140. Griffths CE, Strober BE, van de Kerkhof P et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010 362 : 118 128.
141. Gottlieb A, Menter A, Mendelsohn A et al. Ustekinumab, a human interleukin 1223 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009 373 : 633 640.
142. Nederlandse Verenigung voor Dermatologie en Venerologie (NVDV) and Institute for Healthcare Improvement (CBO). Van Zuiden Communications, 2003.
143. Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005 153 : 486 497.
144. Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009 161 : 987 1019.
145. Nast A, Kopp I, Augustin M et al. German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 2007 299 : 111 138. (Pubitemid 46835379)
146. Puig L, Carrascosa JM, Daudén E et al. Spanish evidence-based guidelines on the treatment of moderate-to-severe psoriasis with biologic agents. Actas Dermosifiliogr 2009 100 : 386 413.
147. Kimball AB, Gladman D, Gelfand JM et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008 58 : 1031 1042.
148. Adalimumab, Summary of Product Characteristics URL http://www.medicines. org.uk/emc/medicine/21201/SPC/Humira+Pen+and+Syringe/
149. Etanercept, Summary of Product Characteristics URL http://www.medicines. org.uk/EMC/medicine/3343/SPC/ Enbrel+25+mg+powder+and+solvent+for+solution+for+injection/
150. Infliximab, Summary of Product Characteristics URL http://www.medicines. org.uk/EMC/medicine/3236/SPC/ Remicade+100mg+powder+for+concentrate+for+solution+for+infusion/
151. Menter A, Papp K, Gu Y et al. American Academy of Dermatology Summer Meeting 2008 p 2428.